Marc-Andre Gagnon – The Conversation

Over 90 per cent of Canadian doctors see pharmaceutical sales representatives. (Shutterstock)

November 12, 2020

Guidelines governing Canadian doctors’ relationships with pharma companies under review

Joel Lexchin, University of Toronto; Barbara Mintzes, University of Sydney; Kelly Holloway, University of Toronto, and Marc-Andre Gagnon, Carleton University

Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA’s current review of its guidelines for doctor/pharma interactions is everybody’s business.

Samples from volunteers are handled in the laboratory at Imperial College in London, on July 30, 2020. Imperial College is working on the development of a COVID-19 vaccine. (AP Photo/Kirsty Wigglesworth)

October 8, 2020

Canada’s COVID‑19 Vaccine Task Force needs better transparency about potential conflicts of interest

Joel Lexchin, University of Toronto; Barbara Mintzes, University of Sydney; Lisa Bero, University of Colorado Anschutz; Marc-Andre Gagnon, Carleton University, and Quinn Grundy, University of Toronto

With lives depending on a vaccine, trust in Canada’s COVID-19 Vaccine Task Force is crucial. Members of the task force need to make any industry links or potential conflicts of interest publicly clear.

Contact Marc-Andre for